2:35
CLL update from ICML17: Current treatment and future directions for patients
Barbara Eichhorst
3:14
Resistance mechanisms to FLT3 inhibitors in AML
Katherine Smith
2:51
Two important therapies for ALL
Dieter Hoelzer
1:47
The potential clinical implications of targeted therapies for DLBCL and why the situation is complex
Clemens Schmitt
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

The content of VJHemOnc is intended for healthcare professionals